Diltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
Sun Pharmaceutical is recalling Diltiazem Hydrochloride Extended-Release Capsules (360 mg) due to failed impurity specifications and dissolution testing found during FDA laboratory evaluation. The recall affects five lot numbers distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall for failed impurity specifications and dissolution testing. No illnesses or injuries have been reported. The quality failures represent a risk of harm (potential therapeutic failure or impurity exposure) without documented injury, fitting the High severity criterion.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling Diltiazem Hydrochloride Extended-Release Capsules, USP, 360 mg. Five lot numbers are affected: HAC3120A (6,912 bottles), HAC3121A (6,792 bottles), HAC4460A (6,816 bottles), HAD0365A (6,744 bottles), and HAD1452A (6,840 bottles). The capsules have been distributed nationwide in the United States.
The recall was initiated because of failed impurity specifications during stability testing and failed dissolution testing at FDA laboratories. Deacetyl Diltiazem Hydrochloride, a degradation product, was found at levels exceeding specifications. The capsules also failed dissolution testing, meaning they did not dissolve properly in the laboratory evaluation.
Pharmacies and healthcare providers may have received these capsules. Patients taking this medication from the affected lots should consult their healthcare provider about their course of action.
The recalled product
- Product
- DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE)
- Brand
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug
- Hazard
- impurity-degradation
- dissolution-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: HAC3120A
- HAC3121A
- Exp. 04/2023
- HAC4460A
- Exp. 10/2023
- HAD0365A
- Exp. 12/2023
- HAD1452A
- Exp. 02/2024.
UPCs (5)
- 0347335679830
- 0347335677836
- 0347335676839
- 0347335678833
- 0347335675832
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DILTIAZEM HYDROCHLORIDE
- HighGlenmark Diltiazem Extended-Release Capsules recalled for manufacturing deviations
FDA (Drugs) · 2025-04-16
- HighDiltiazem Hydrochloride Capsules Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem extended-release capsules recalled for manufacturing impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Extended-Release Capsules Recalled for Manufacturing Impurity
FDA (Drugs) · 2024-12-11
- HighDiltiazem Hydrochloride Capsules Recalled Due to Manufacturing Impurity
FDA (Drugs) · 2024-12-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27